Investigational Drug Information for Fenebrutinib
✉ Email this page to a colleague
What is the drug development status for Fenebrutinib?
Fenebrutinib is an investigational drug.
There have been 7 clinical trials for Fenebrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 17th 2021.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Leukemia, Lymphoid. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and fifty-two international patents.
Summary for Fenebrutinib
| US Patents | 8 |
| International Patents | 152 |
| US Patent Applications | 48 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2021-03-17) |
| Vendors | 40 |
Recent Clinical Trials for Fenebrutinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 2 |
| Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
| A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
Clinical Trial Summary for Fenebrutinib
Top disease conditions for Fenebrutinib
Top clinical trial sponsors for Fenebrutinib
US Patents for Fenebrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| fenebrutinib | ⤷ Try a Trial | Heteroaryl pyridone and aza-pyrodine compounds | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| fenebrutinib | ⤷ Try a Trial | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| fenebrutinib | ⤷ Try a Trial | Therapeutic compounds and compositions, and methods of use thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| fenebrutinib | ⤷ Try a Trial | Process for preparing BTK inhibitors | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| fenebrutinib | ⤷ Try a Trial | Heteroaryl pyridone and aza-pyridone compounds | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| fenebrutinib | ⤷ Try a Trial | Heteroaryl pyridone and aza-pyridone compounds | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fenebrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| fenebrutinib | Argentina | AR088641 | 2031-11-03 | ⤷ Try a Trial |
| fenebrutinib | Argentina | AR117501 | 2031-11-03 | ⤷ Try a Trial |
| fenebrutinib | Australia | AU2012332365 | 2031-11-03 | ⤷ Try a Trial |
| fenebrutinib | Australia | AU2016273930 | 2031-11-03 | ⤷ Try a Trial |
| fenebrutinib | Australia | AU2018201557 | 2031-11-03 | ⤷ Try a Trial |
| fenebrutinib | Australia | AU2019216728 | 2031-11-03 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
